Skip to content
    NTRA
    Earnings call· Dec 2024(Q4 FY24)

    Natera, Inc. NTRA

    Feb 27, 2025 Source

    Executive summary

    Natera Q4 FY24 — Strong Revenue Growth and Cash Flow Generation with Robust Pipeline Progress

    Natera concluded a transformational year with strong Q4 FY24 results, driven by significant revenue and volume growth across its portfolio, particularly Signatera. The company achieved record gross margins and generated substantial cash flow, enabling reinvestment into its platform and pipeline. Management is cautiously optimistic about continued momentum into 2025, focusing on expanding reimbursement, leveraging AI tools, and advancing clinical trials for its core products and early cancer detection.

    Highlights

    5

    • Q4 revenues reached $476 million, marking a 53% year-on-year increase and exceeding pre-announcement by $4 million.

    • Gross margins significantly improved to 63% in Q4 (59% excluding true-ups), up from 51% a year ago, driven by COGS reduction and realized pricing.

    • The company generated $46 million in cash flow in Q4, contributing to $86 million for the full year, demonstrating strong operational efficiency.

    • Signatera clinical volumes surged by approximately 60% year-on-year in Q4 2023, with nearly 15,000 units of growth over Q3 2024.

    • Secured Medicare coverage for Signatera in non-small cell lung cancer (Stages I-III) and saw NCCN strengthen its position on cell-free DNA testing in colorectal cancer and Merkel cell carcinoma.

    Concerns

    2

    • The 2025 gross margin guide anticipates some short-term headwinds from the launch of two complementary MRD products (tumor-naive MRD and genome backbone) which do not yet have optimized unit economics.

    • ASPs from biomarker laws are expected to flow in gradually over time, with early wins but no significant level of traction required in the 2025 guidance.

    Guidance & targets

    7
    CategoryTargetConfidence
    Full-year 2025 Revenue
    $1.87 billion to $1.95 billion
    high materiality
    High
    Full-year 2025 Implied Revenue Growth Rate (ex-true-ups)
    roughly 24%
    high materiality
    High
    Full-year 2025 Gross Margin
    continued progress above 59%
    high materiality
    High
    Signatera Sequential Unit Growth
    modestly outpace 8,000 to 10,000 units
    medium materiality
    High
    Cash Flow
    cash flow positive result again
    high materiality
    High
    Tissue-free assay launch
    launch expected in mid-2025
    medium materiality
    High
    FDA enabling FINE study enrollment
    expected to enroll over the next 18 months
    medium materiality
    High

    Operational metrics

    25
    Revenue
    $476 millionup 53% year-on-year
    Q4 FY24

    Exceeded pre-announcement of $472 million by $4 million.

    Total Volumes Growth
    26%YoY
    Q4 FY24

    Included excellent showing for Signatera unit growth.

    Gross Margin
    63%up from 51% a year ago
    Q4 FY24

    Significant improvement driven by COGS and realized pricing. Included a 3% true-up benefit.

    Cash Flow Generation
    $46 million
    Q4 FY24

    Represents a significant new record for Natera.

    Total Cash Flow Generation
    $86 million
    FY24

    Full year cash flow.

    Cash and Investments Balance
    just under $1 billion
    Q4 FY24

    Follows the retirement of convertible notes early in Q4.

    Signatera Clinical Volumes Growth
    approximately 60%vs Q4 2023
    Q4 FY24

    Reflects a transformational year for Signatera.

    Organ Health Volumes Growth
    almost 50%year-on-year
    Q4 FY24

    Volumes continue to ramp across the portfolio.

    Signatera Clinical Average Selling Price (ASP)
    roughly $1,100
    Q4 FY24

    Continued steady progress for both Panorama and Horizon ASPs as well.

    Revenue per test potential
    double
    several years out

    Potential to double revenue from current volumes by expanding coverage and reimbursement for tests already being run.

    Cost of Goods Sold per unit
    continued to fall
    2024

    Driving significant improvement in gross margins.

    Data-related Contracts Signed
    over $10 million
    YTD 2025

    Positive early momentum in data initiatives.

    Fetal RhD Test Sensitivity
    100%
    clinical validation study

    Published in the Journal of Obstetrics and Gynaecology in November.

    Fetal RhD Test Specificity
    99.3%
    clinical validation study

    Published in the Journal of Obstetrics and Gynaecology in November.

    PEDAL Study Enrollment
    more than 580 patients
    study duration

    Prospective clinical trial for kidney transplant patients evaluating donor DNA monitoring during rejection treatment.

    DEFINE Study Patients and Time Points
    more than 100 patients and over 1,000 time points
    study duration

    Large-scale prospective multicenter longitudinal study of donor DNA in heart transplant patients.

    Early Cancer Detection Technology Sensitivity
    95%
    prospective validation

    With minimal degradation of performance in the asymptomatic screen detected population.

    Early Cancer Detection Technology Specificity
    91%
    prospective validation

    With minimal degradation of performance in the asymptomatic screen detected population.

    Advanced Adenoma Trial Sensitivity
    18%
    trial results

    Found in patients analyzed for the study.

    Advanced Adenoma Trial Specificity
    91%
    trial results

    Found in patients analyzed for the study.

    Medicare Rate for Early Cancer Detection
    $9.20
    current

    Confirmed Medicare rate for the clinical lab fee schedule.

    ADLT Pricing Potential for Early Cancer Detection
    $1,500 range
    future

    Possible if FDA approval is sought, elevating the opportunity for Natera.

    Cancer Exome Database Size
    over 200,000
    current

    Believed to be one of the largest in the world, leveraged for improving patient care and identifying new signatures.

    Signatera Genome-based Product Variants Tracked
    64
    current

    Chosen to optimize sensitivity and specificity while controlling COGS.

    Signatera Exome-based Product Variants Tracked
    16
    current

    Optimal number for exome, balancing performance and COGS.

    Product announcements

    2
    ProductTypeDetails
    Tissue-free assaylaunch
    FDA enabling FINE studylaunch

    Deals & partnerships

    1
    InvitaeHelped augment women's health volumes.

    Contributed to strong organic growth in Women's Health.

    Risks & headwinds

    3
    Launch of complementary MRD products (tumor-naive MRD and genome backbone) with unoptimized unit economics.short-term

    short-term headwind for margins

    Mitigation: Uptake is a healthy signal for longer-term development of the Signatera franchise, implying future optimization.

    Biomarker laws' impact on ASPs will flow in gradually.over time (this year or next year)

    expected to flow in gradually over time

    Mitigation: Formal policy publications create ammunition to press other plans; expectation of conservative positive improvement.

    Revenue true-ups are lumpy and unpredictable.quarter-to-quarter

    hard to predict quarter-to-quarter

    Mitigation: Guidance does not attempt to forecast true-ups; focus on underlying business delivery. Expectation for true-ups to moderate over time as ASP growth moderates.

    What to watch in Q1 FY25

    5

    Signatera sequential volume growth

    Q1 FY25 and beyond
    Currentnearly 15,000 units over Q3 2024
    Targetmodestly outpace 8,000 to 10,000 units

    Why it matters

    Indicates continued market penetration and adoption of Signatera, a key growth driver.

    The guide presumes we will modestly outpace that 8,000 to 10,000 level in 2025.

    Q&A highlights

    6

    Does the 'double Signatera revenue at current volume' imply ASPs of ~$2,000? How is the genome-based product resonating with pharma/biotech customers, and is it factored into guidance?

    Steve Chapman clarified that doubling revenue per test refers to getting paid for tests currently run but not reimbursed, which could effectively double revenue from existing volumes. Solomon Moshkevich noted strong reception for the genome-based product, primarily for clinical research, and highlighted Natera's flexible multiplex PCR technology for both targeted and broader panels.

    “we think we could see the revenue per test effectively double as we start to get paid for some of the tests that we run today that are already baked into our COGS we're not getting paid on.”

    asked by Doug Schenkel (Wolfe Research) · answered by Steve Chapman

    2 min read6 chapters

    Detailed Narrative

    01

    Q4 FY24 Financial and Operational Momentum

    Natera concluded 2024 with significant momentum, reporting Q4 revenues of $476 million, a 53% year-on-year increase, and volumes up 26%. Gross margins reached 63% (59% ex-true-up📎s), a substantial improvement from 51% a year prior, driven by COGS reductions and improved realized pricing. The company generated $46 million in cash flow in Q4, contributing to $86 million for the full year, and ended with nearly $1 billion in cash and minimal debt.

    02

    Signatera's Expanding Clinical Utility and Reimbursement

    Signatera clinical volumes grew approximately 60% year-on-year in Q4 2023, with nearly 15,000 units added over Q3 2024. The company secured Medicare coverage for Signatera in non-small cell lung cancer (Stages I-III) for recurrence monitoring and immunotherapy monitoring. Recent NCCN guideline updates also strengthened the position of ctDNA testing in colorectal cancer and Merkel cell carcinoma, with specific reference to Signatera for surveillance in the latter.

    03

    Advancements in Early Cancer Detection (ECD)

    Natera presented its first prospective validation of its ECD technology, demonstrating 95% sensitivity and 91% specificity. Further encouraging results were seen in CRC sensitivity in an independent dataset (majority Stage I and II) and an 18% sensitivity for advanced adenoma with 91% specificity in a prospective trial. Based on these results, the company is initiating the FDA-enabling FINE study, expected to enroll over the next 18 months, with a Medicare rate confirmed at $9.20 and potential ADLT pricing up to $1,500.

    04

    Organ Health and Women's Health Progress

    In organ health, two novel studies for Prospera, PEDAL (kidney transplant rejection monitoring) and DEFINE (heart transplant monitoring), are expected to read out in the coming months⏳, potentially impacting the standard of care. In women's health, the noninvasive fetal RhD test saw growing demand and adoption, supported by a clinical validation study showing 100% sensitivity and 99.3% specificity, and secured commercial coverage from a large national payer.

    05

    Innovation in Technology and Data Monetization

    Natera continues to deploy cutting-edge AI and large language models to optimize productivity, improve customer experience, and identify new prognostic signatures from its extensive genomic data. The company boasts one of the largest cancer exome databases globally, with over 200,000 cancer exomes. This data initiative has already secured over $10 million in contracts in 2025, highlighting a new revenue stream.

    06

    Strategic Investments and Future Outlook

    The company plans to reinvest its generated cash flows into the business in 2025, particularly in R&D and SG&A, to enhance growth in 2026 and beyond. This includes significant focus on MRD in oncology, clinical trials, product line extensions, and the FDA-enabling ECD study. Management believes these investments will yield high returns and further solidify Natera's market position.

    AI-generated summary of the company’s earnings call. Not investment advice.